Human tumor-infiltrating myeloid cells: Phenotypic and functional diversity

Frontiers in Immunology

Volumn 8, Issue FEB, 2017, Pages

  Elliott, Louise A ^a   Doherty, Glen A ^a   Sheahan, Kieran ^a   Ryan, Elizabeth J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Immune cell phenotyping; Macrophages; Monocytes; Myeloid derived suppressor cells; Neutrophils; Oncoimmunology; Tumor microenvironment

Indexed keywords

ANGIOPOIETIN RECEPTOR; ARGINASE 1; BLZP 45; CARLUMAB; CB 1158; CD11B ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CD45RA ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CCR8; EMACTUZUMAB; GELATINASE B; HLA DR ANTIGEN; HUMAX IL 8; INDOLEAMINE 2,3 DIOXYGENASE; INDOXIMOD; IOD1 PEPTIDE VACCINE; LY 3022855; MONOCLONAL ANTIBODY; N [2 (2,3 DIFLUOROBENZYLTHIO) 6 (2,3 DIHYDROXY 1 METHYLPROPOXY) 4 PYRIMIDINYL] 1 AZETIDINESULFONAMIDE; PLEXIDARTINIB; PLOZALIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; REPARIXIN; SOMATOMEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

BONE MARROW CELL; CANCER GROWTH; CANCER INFILTRATION; CELL INVASION; CELL PROLIFERATION; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASM; NEUTROPHIL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

EID: 85014307554     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00086     Document Type: Review

References (129)

1. Prat A, Pineda E, Adamo B, Galvan P, Fernandez A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast (2015) 24(2):526-35. doi:10.1016/j.breast.2015.07.008
2. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity (2016) 44(3):698-711. doi:10.1016/j.immuni.2016.02.025
3. Balermpas P, Rödel F, Liberz R, Oppermann J, Wagenblast J, Ghanaati S, et al. Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br J Cancer (2014) 111(8):1509-18. doi:10.1038/bjc.2014.446
4. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer (2013) 108(4):914-23. doi:10.1038/bjc.2013.32
5. Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One (2013) 8(2):e57114. doi:10.1371/journal.pone.0057114
6. Mahmoud SMA, Lee AHS, Paish EC, Macmillan RD, Ellis IO, Green AR. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol (2012) 65(2):159-63. doi:10.1136/jclinpath-2011-200355
7. Cunha LL, Morari EC, Guihen ACT, Razolli D, Gerhard R, Nonogaki S, et al. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol (2012) 77(6):918-25. doi:10.1111/j.1365-2265.2012.04482.x
8. Punt S, Fleuren G, Jan KE, Lubberts E, Trimbos JB, Jordanova ES, et al. Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. Oncoimmunology (2015) 4(1):e984539. doi:10.4161/2162402X.2014.984539
9. Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology (2016) 150(7):1646.e-58.e. doi:10.1053/j.gastro.2016.02.040
10. Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene (2016) 35:1-11. doi:10.1038/onc.2016.107
11. Ginhoux F, Guilliams M. Tissue-resident macrophage ontogeny and homeostasis. Immunity (2016) 44(3):439-49. doi:10.1016/j.immuni.2016.02.024
12. Hu H, Hang JJ, Han T, Zhuo M, Jiao F, Wang LW. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Tumor Biol (2016) 37(7):8657-64. doi:10.1007/s13277-015-4741-z
13. Xue J, Chmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity (2014) 40(2):274-88. doi:10.1016/j.immuni.2014.01.006
14. Mowat AM, Bain CC. Mucosal macrophages in intestinal homeostasis and inflammation. J Innate Immun (2011) 3(6):550-64. doi:10.1159/000329099
15. Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest (2013) 123(4):1580-9. doi:10.1172/JCI60083
16. Cavnar MJ, Zeng S, Kim TS, Sorenson EC, Ocuin LM, Balachandran VP, et al. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J Exp Med (2013) 210(13):2873-86. doi:10.1084/jem.20130875
17. Eruslanov EB, Stoffs T, Kim WJ, Daurkin K, Gilbert SM, Su LM, et al. Expansion of CCR8+ inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas. Clin Cancer Res (2013) 72(2):181-204. doi:10.1158/1078-0432
18. Eruslanov EB, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dham P, et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer (2012) 130(5):1109-19. doi:10.1002/ijc.26123
19. Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity (2013) 38(2):336-48. doi:10.1016/j.immuni.2012.10.018
20. Li C, Luo X, Lin Y, Tang X, Ling L, Wang L, et al. A higher frequency of CD14+CD169+ monocytes/macrophages in patients with colorectal cancer. PLoS One (2015) 10(10):e0141817. doi:10.1371/journal.pone.0141817
21. Sconocchia G, Zlobec I, Lugli A, Calabrese D, Karamitopoulou E, Patsouris ES. Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer (2012) 128(11):2663-72. doi:10.1002/ijc.25609
22. Sun HL, Zhou X, Xue Y, Wang K, Shen YF, Mao JJ, et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol (2012) 18(25):3303-9. doi:10.3748/wjg.v18.i25.3303
23. Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, et al. Tumor-associated neutrophils stimulate T cell resposnses in early-stage human lung cancer. J Clin Invest (2014) 124(12):1-15. doi:10.1172/JCI77053
24. Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA, et al. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res (2012) 18(19):5212-23. doi:10.1158/1078-0432.CCR-12-1108
25. Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, Sugarbaker DJ. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer (2011) 117(22):5234-44. doi:10.1002/cncr.26143
26. Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CTBP2. Immunity (2013) 39(3):611-21. doi:10.1016/j.immuni.2013.08.025
27. Khaled YS, Ammori BJ, Elkord E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. J Immunol Res (2014) 2014:879897. doi:10.1155/2014/879897
28. Panni RZ, Sanford DE, Belt BA, Mitchem JB, Worley LA, Goetz BD, et al. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunol Immunother (2014) 63(5):513-28. doi:10.1007/s00262-014-1527-x
29. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, et al. IL4R + myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 182(10):6562-8. doi:10.4049/jimmunol.0803831
30. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Camus M, Gerger A, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313:1960-4. doi:10.1126/science.1129139
31. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell (2014) 26(5):638-52. doi:10.1016/j.ccell.2014.09.007
32. Elpek KG, Cremasco V, Shen H, Harvey CJ, Wucherpfennig KW, Goldstein DR, et al. The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells. Cancer Immunol Res (2014) 2(6):655-68. doi:10.1158/2326-6066
33. Forget MA, Voorhees JL, Cole SL, Dakhlallah D, Patterson IL, Gross AC, et al. Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. PLoS One (2014) 9(6):e98623. doi:10.1371/journal.pone.0098623
34. De Palma M, Venneri MA, Galli R, Sergi LS, Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell (2005) 8(3):211-26. doi:10.1016/j.ccr.2005.08.002
35. Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res (2010) 70(13):5270-80. doi:10.1158/0008-5472
36. Wang X, Dai Z, Wu X, Wang K, Wang X. Distinct RNA transcriptome patterns are potentially associated with angiogenesis in Tie2-expressing monocytes. Gene (2016) 580(1):1-7. doi:10.1016/j.gene.2015.12.065
37. Ji J, Zhang G, Sun B, Yuan H, Huang Y, Zhang J, et al. The frequency of tumor-infiltrating tie-2-expressing monocytes in renal cell carcinoma: its relationship to angiogenesis and progression. Urology (2013) 82(4):974. doi:10.1016/j.urology.2013.05.026
38. Matsubara T, Kanto T, Kuroda S, Yoshio S, Higashitani K, Kakita N, et al. TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology (2013) 57(4):1416-25. doi:10.1002/hep.25965
39. Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol (2007) 178:7405-11. doi:10.4049/jimmunol.178.11.7405
40. Schauer D, Starlinger P, Reite C, Jahn N, Zajc P, Buchberger E, et al. Intermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer. PLoS One (2012) 7(9):e44450. doi:10.1371/journal.pone.0044450
41. Goede V, Coutelle O, Shimabukuro-Vornhagen A, Holtick U, Neuneier J, Koslowsky TC, et al. Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer. Cancer Invest (2012) 30(3):225-30. doi:10.3109/07357907.2011.636114
42. Chen J, Deng Q, Pan Y, He B, Ying H, Sun H, et al. Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. FEBS Open Bio (2015) 5:502-7. doi:10.1016/j.fob.2015.05.003
43. Yin Y, Wang J, Wang X, Gu L, Pei H, Kuai S, et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: a meta-analysis. Clinics (2015) 70(7):524-30. doi:10.1002/ijc.30060
44. Shen M, Hu P, Donskov F, Wang G, Liu Q, Du J. Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS One (2014) 9(6):e98259. doi:10.1371/journal.pone.0098259
45. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med (2015) 21(8):938-45. doi:10.1038/nm.3909
46. Amicarella F, Muraro MG, Hirt C, Cremonesi E, Padovan E, Mele V, et al. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut (2015) 1-13. doi:10.1136/gutjnl-2015-310016
47. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 16(3):183-94. doi:10.1016/j.ccr.2009.06.017
48. Trellakis S, Farjah H, Bruderek K, Dumitru CA, Hoffmann TK, Lang S, et al. Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int J Immunopathol Pharmacol (2011) 24(3):683-93. doi:10.1177/039463201102400314
49. Kastelan Z, Lukac J, Derezic D, Pasini J, Kusic Z, Sosic H, et al. Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Anticancer Res (2003) 23(6):5185-9.
50. Jablonska E, Puzewska W, Grabowska Z, Jablonski J, Talarek L. VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine (2005) 30(3):93-9. doi:10.1016/j.cyto.2004.12.004
51. Jablonska E, Jablonski J, Marcinczyk M, Grabowska Z, Piotrowski L. The release of soluble forms of TRAIL and DR5 by neutrophils of oral cavity cancer patients. Folia Histochem Cytobiol (2008) 46(2):177-83. doi:10.2478/v10042-008-0027-2
52. Khanh DT, Mekata E, Mukaisho K, Sugihara H, Shimizu T, Shiomi H, et al. Prognostic role of CD10+ myeloid cells in association with tumor budding at the invasion front of colorectal cancer. Cancer Sci (2011) 102(9):1724-33. doi:10.1111/j.1349-7006.2011.01987.x
53. Rogers AC, Gibbons D, Hanly AM, Hyland JMP, O'Connell R, Winter D, et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol (2014) 27(1):156-62. doi:10.1038/modpathol.2013.124
54. Singhal S, Bhojnagarwala PS, O'Brien S, Moon EK, Garfall AL, Rao AS, et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell (2016) 30(1):120-35. doi:10.1016/j.ccell.2016.06.001
55. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cell by tumours. Nat Rev Immunol (2012) 12(4):253-68. doI:10.1038/nri3175
56. Gabrilovich DI, Nagaraj S. Myeloid-derived-supressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9(3):162-74. doi:10.1038/nri2506
57. Uan XY, Hao XKZ, Ia YCX, Hu XZ, Yuan X-K, Zhao X-K, et al. Increased circulating cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J Int Med Res (2011) 39(4):1381-91. doi:10.1177/147323001103900424
58. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol (2013) 190(7):3783-97. doi:10.4049/jimmunol.1201449
59. Heuvers ME, Muskens F, Bezemer K, Lambers M, Dingemans AC, Groen HJM, et al. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients. Lung Cancer (2013) 81(3):468-74. doi:10.1016/j.lungcan.2013.06.005
60. Liu CY, Wang YU, Wang M, Chih L, Feng P, Hao K, et al. Population alterations of l-arginase-and inducible nitric oxide synthase-expressed CD11b+/CD14-/CD15+/CD33 + myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol (2010) 136(1):35-45. doi:10.1007/s00432-009-0634-0
61. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun (2016) 7:12150. doi:10.1038/ncomms12150
62. Alfaro C, Teijeira A, Onate C, Perez G, Fernandez de Sanmamed M, Andueza MP, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res (2016) 22(15):3924-6. doi:10.1158/1078-0432.CCR-15-2463
63. Diaz-Montero CM, Salem ML, Nishimura MI, Garett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastasic burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2009) 58(1):49-59. doi:10.1007/s00262-008-0523-4
64. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol (2011) 13(6):591-9. doi:10.1093/neuonc/nor042
65. Shen P, Wang A, He M, Wang Q, Zheng S. Increased circulating Lin-/low CD33+ HLA-DR-myeloid-derived suppressor cells in hepatocellular carcinoma patients. Hepatol Res (2014) 44(6):639-50. doi:10.1111/hepr.12167
66. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells. Gastroenterology (2008) 135(1):234-43. doi:10.1053/j.gastro.2008.03.020
67. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res (2010) 70(11):4335-45. doi:10.1158/0008-5472.CAN-09-3767
68. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One (2014) 9(2):e87705. doi:10.1371/journal.pone.0087705
69. Pico de Coaña Y, Poschke I, Gentilcore GM, Mao Y, Nyström M, Hansson J, et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res (2013) 1(3):158-62. doi:10.1158/2326-6066.CIR-13-0016
70. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE 2-induced CXCL 12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res (2011) 71(24):7463-70. doi:10.1158/0008-5472.CAN-11-2449
71. Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother (2012) 61(9):1373-85. doi:10.1007/s00262-011-1178-0
72. Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol Immunother (2014) 63(2):175-83. doi:10.1007/s00262-013-1502-y
73. Brusa D, Simone M, Gontero P, Spadi R, Racca P, Micari J, et al. Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison. Int J Urol (2013) 20(10):971-8. doi:10.1111/iju.12086
74. Vuk-Pavlovic S, Bulur P, Lin Y, Qin R, Szumlanski CL, Zhao X, et al. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate (2010) 70(4):443-55. doi:10.1002/pros.21078
75. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 15(6):2148-57. doi:10.1158/1078-0432.CCR-08-1332
76. Rodriguez PC, ErnstoffMS, Hernandez C, Atkins M, Sierra R, Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2010) 69(4):1553-60. doi:10.1158/0008-5472.CAN-08-1921
77. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor bearing mice. J Immunol (2008) 4(164):5791-802. doi:10.4049/jimmunol.181.8.5791
78. Sagiv JY, Michaeli J, Assi S, Mishalian I, Kisos H, Levy L, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep (2015) 10(4):562-73. doi:10.1016/j.celrep.2014.12.039
79. Koffel R, Meshcheryakova A, Warszawska J, Hennig A, Wagner K, Almut J, et al. Regular article monocytic cell differentiation from band-stage neutrophils under inflammatory conditions via MKK6 activation. Blood (2014) 124(17):2713-25. doi:10.1182/blood-2014-07-588178
80. Li X, Yao W, Yuan Y, Chen P, Li B, Li J, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut (2015) 1-11. doi:10.1136/gutjnl-2015-310514
81. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 475(7355):222-5. doi:10.1038/nature10138
82. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res (2000) 6:3282-9.
83. Bailey C, Negus R, Morris A, Ziprin P, Goldin R, Allavena P, et al. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis (2007) 24(2):121-30. doi:10.1007/s10585-007-9060-3
84. Wang H, Zhang Q, Kong H, Zeng Y, Hao M, Yu T, et al. Monocyte chemotactic protein-1 expression as a prognosic biomarker in patients with solid tumor: a meta analysis. Int J Clin Exp Pathol (2014) 7(7):3876-86.
85. Lanca T, Costa MF, Goncalves-Sousa N, Rei M, Grosso AR, Penido C, et al. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic gammadelta T lymphocytes to tumor beds. J Immunol (2013) 190(12):6673-80. doi:10.4049/jimmunol.1300434
86. Spary LK, Salimu J, Webber JP, Clayton A, Mason MD. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14 PD-L1 phenotype in prostate cancer. Oncoimmunology (2014) 3(9):e955331. doi:10.4161/21624011.2014.955331
87. Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med (2015) 212(7):1043-59. doi:10.1084/jem.20141836
88. Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol (2013) 71:1041-50. doi:10.1007/s00280-013-2099-8
89. Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Simon J, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs (2013) 31:760-8. doi:10.1007/s10637-012-9869-8
90. Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science (2016) 352(6288):aad3018. doi:10.1126/science.aad3018
91. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 19(10):1264-72. doi:10.1038/nm.3337
92. Zhu Y, KnolfhoffLB, Meyer AM, Nywening MT, West BL, Luo J, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to t cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res (2015) 19(2):161-9. doi:10.1158/0008-5472
93. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol (2016) 18(4):557-64. doi:10.1093/neuonc/nov245
94. Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol (2015) 16(8):949-56. doi:10.1016/S1470-2045(15)00132-1
95. Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget (2014) 5(18):8136-46. doi:10.18632/oncotarget.2357
96. Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen S, Kiaer BJ, et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2, 3 dioxygenase. Clin Cancer Res (2014) 20(1):221-32. doi:10.1158/1078-0432.CCR-13-1560
97. Steele CW, Karim SA, Leach J, Bailey P, Upstill-Goddard R, Rishi L, et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell (2016) 29(2):832-45. doi:10.1016/j.ccell.2016.04.014
98. Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med (2014) 6(237):237ra67. doi:10.1126/scitranslmed.3007974
99. Silva T, Ribeiro FL, Oliveira-Neto HH, Watanabe S, Alencar Rde C, Fukada SY, et al. Dual role of CCL3/CCR1 in oral squamous cell carcinoma: implications in tumor metastasis and local host defense. Oncol Rep (2007) 18(5):1107-13. doi:10.3892/or.18.5.1107
100. Chang LY, Lin Y, Chang M, Jayashri H, Ching T, Chen TW, et al. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8 + T cells in colon cancer by T-regulatory cells. Cancer Res (2012) 72(5):1092-102. doi:10.1158/0008-5472
101. Zumwalt TJ, Arnold M, Goel A, Boland CR. Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration. Oncotarget (2015) 6(5):2981-91. doi:10.18632/oncotarget.3205
102. Chittezhath M, Dhillon M, Kaur Lim J, Yuan L, Damya S, Irina NT, et al. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity (2014) 41(5):815-29. doi:10.1016/j.immuni.2014.09.014
103. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol (2004) 14(11):628-38. doi:10.1016/j.tcb.2004.09.016
104. Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, et al. M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment. Cancer Res (2015) 76(1):35-43. doi:10.1158/0008-5472
105. Lin BEY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 193(6):727-40. doi:10.1084/jem.193.6.727
106. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int (2009) 59(5):300-5. doi:10.1111/j.1440-1827.2009.02369.x
107. Yang L, Wu Q, Xu L, Zhang W, Zhu Y, Liu H, et al. Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma. BMC Cancer (2015) 15(67):67. doi:10.1186/s12885-015-1076-5
108. Richardsen E, Uglehus RD, Due J, Busch C, Busund LTR. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopathology (2008) 53(1):30-8. doi:10.1111/j.1365-2559.2008.03058.x
109. Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med (2015) 12(3):201-8. doi:10.7497/j.issn.2095-3941.2015.0046
110. Strauss L, Sangaletti S, Consonni FM, Colombo MP, Porta C, Anselmo A, et al. RORC1 regulates tumor-promoting "emergency" granulo-monocytopoiesis. Cancer Cell (2015) 28(2):253-69. doi:10.1016/j.ccell.2015.07.006
111. Sanmamed MF, Carranza-Rua O, Alfaro C, Oñate C, Martín-Algarra S, Perez G, et al. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res (2014) 20(22):5697-707. doi:10.1158/1078-0432.CCR-13-3203
112. Mendonca MA, Souto FO, Micheli DC, Alves-Filho JC, Cunha FQ, Murta E, et al. Mechanisms affecting neutrophil migration capacity in breast cancer patients before and after chemotherapy. Cancer Chemother Pharmacol (2014) 73(2):317-24. doi:10.1007/s00280-013-2348-x
113. O'Toole A, Michielsen AJ, Nolan B, Tosetto M, Sheahan K, Mulcahy HE, et al. Tumour microenvironment of both early-and late-stage colorectal cancer is equally immunosuppressive. Br J Cancer (2014) 111:927-32. doi:10.1038/bjc.2014.367
114. Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia XF, et al. Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res (2016) 76(4):818-30. doi:10.1158/0008-5472.CAN-15-0977
115. Munder M. Arginase: an emerging key player in the mammalian immune system: review. Br J Pharmacol (2009) 158(3):638-51. doi:10.1111/j.1476-5381.2009.00291.x
116. Raber P, Ochoa AC, Rodriguez PC. Metabolism of l-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest (2012) 41(6-7):614-34. doi:10.3109/08820139.2012.680634
117. Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A. Inhibition of tumor-derived prostaglandin-E2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res (2014) 20(15):4096-106. doi:10.1158/1078-0432.CCR-14-0635
118. Ascierto PA, Marincola FM. 2015: the year of anti-PD-1/PD-L1s against melanoma and beyond. EBioMedicine (2015) 2(2):92-3. doi:10.1016/j.ebiom.2015.01.011
119. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med (2015) 373(20):2509-20. doi:10.1056/NEJMoa1500596
120. Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer (2015) 112(9):1421-7. doi:10.1038/bjc.2015.124
121. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 384(9948):1109-17. doi:10.1016/S0140-6736(14)60958-2
122. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun (2015) 6:6692. doi:10.1038/ncomms7692
123. Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res (2016) 3(4):326-32. doi:10.1158/2326-6066.CIR-14-0133
124. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1 A, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 211(5):781-90. doi:10.1084/jem.20131916
125. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration invasion, and metastasis. Cell (2006) 124(2):263-6. doi:10.1016/j.cell.2006.01.007
126. Su S, Liu Q, Chen J, Chen J, Chen F, He C, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell (2014) 25(5):605-20. doi:10.1016/j.ccr.2014.03.021
127. Pignatelli J, Goswami S, Jones JG, Rohan TE, Pieri E, Chen X, et al. Invasive breast carcinoma cells from patients exhibit MenaINV-and macrophage-dependent transendothelial migration. Sci Signal (2014) 7(353):ra112. doi:10.1126/scisignal.2005329
128. Zhao L, Wu Y, Xie XD, Chu YF, Li JQ, Zheng LC-. Met identifies a population of matrix metalloproteinase 9-producing monocytes in peritumoural stroma of hepatocellular carcinoma. J Pathol (2015) 237(3):319-29. doi:10.1002/path.4578
129. Napolitano M, D'Alterio C, Cardone E, Trotta AM, Pecori B, Rega D, et al. Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. Oncotarget (2015) 6(10):8261-70. doi:10.18632/oncotarget.3014